Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00105586
Status:
COMPLETED
Last Update Posted:
2017-05-08
First Post:
2005-03-15
Brief Title:
Drug Therapy for Generalized Anxiety Disorder Among the Elderly
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Pharmacotherapy of Late-Life Generalized Anxiety Disorder
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the efficacy of escitalopram Lexapro an anti-anxiety drug for generalized anxiety disorder GAD and the ways genetics affect response to treatment for GAD in elderly individuals
Detailed Description:
GAD is a serious public health issue particularly among the elderly prevalence of the condition is high and functional burden on those with the illness is significant GAD is associated with irregular levels of neurotransmitters chemicals that carry messages across nerve endings Serotonin is a neurotransmitter that helps regulate mood and emotions increased levels of serotonin have been shown to reduce anxiety Standard treatment for GAD typically involves selective serotonin reuptake inhibitors SSRIs drugs that reduce serotonin re-entry into nerve cells Escitalopram is an SSRI that is well tolerated and highly specific for the serotonin transporter SERT The primary aim of this study is to examine the efficacy of escitalopram in reducing anxiety symptoms among elderly GAD patients Additional aims include examining the efficacy of escitalopram for improving function quality of life and neuropsychological functioning and examining whether genetic variation in the SERT gene influences these participants response to treatment
Participants will be randomly assigned to receive either escitalopram or placebo for 12 weeks there is also a 12 week open label extension in which all participants will receive escitalopram Participants will have weeklybiweekly study visits during these visits participants will complete self-report questionnaires on functional ability and anxiety symptoms Blood collection and cognitive testing through various tasks will also occur
Participants will be randomly assigned to receive either escitalopram or placebo for 12 weeks there is also a 12 week open label extension in which all participants will receive escitalopram Participants will have weeklybiweekly study visits during these visits participants will complete self-report questionnaires on functional ability and anxiety symptoms Blood collection and cognitive testing through various tasks will also occur
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MH070547 | NIH | None | httpsreporternihgovquickSearchR01MH070547 |